Drug Trial Radar · NCT07951190
An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Nov 25, 2032
Study completion Nov 25, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.
Conditions
- Complement Mediated Diseases e.g. PNH, IgAN
Interventions
IptacopanDrug
Participants \>12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to \<12 years will receive weight-based dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.